These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 8297739

  • 1. Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer.
    Ardizzoni A, Venturini M, Sertoli MR, Giannessi PG, Brema F, Danova M, Testore F, Mariani GL, Pennucci MC, Queirolo P.
    Br J Cancer; 1994 Feb; 69(2):385-91. PubMed ID: 8297739
    [Abstract] [Full Text] [Related]

  • 2. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
    O'Shaughnessy JA, Denicoff AM, Venzon DJ, Danforth D, Pierce LJ, Frame JN, Bastian A, Ghosh B, Goldspiel B, Miller L.
    Ann Oncol; 1994 Oct; 5(8):709-16. PubMed ID: 7826903
    [Abstract] [Full Text] [Related]

  • 3. Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer.
    Venturini M, Del Mastro L, Testore F, Danova M, Garrone O, Lanfranco C, Latini F, Sertoli MR, Lionetto R, Queirolo P, Ardizzoni A, Rosso R.
    Cancer Chemother Pharmacol; 1996 Oct; 38(6):487-94. PubMed ID: 8823488
    [Abstract] [Full Text] [Related]

  • 4. A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy.
    O'Shaughnessy JA, Venzon DJ, Gossard M, Noone MH, Denicoff A, Tolcher A, Danforth D, Jacobson J, Keegan P, Miller L, Chow C, Goldspiel B, Cowan KH.
    Blood; 1995 Oct 15; 86(8):2913-21. PubMed ID: 7579383
    [Abstract] [Full Text] [Related]

  • 5. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
    Jones SE, Schottstaedt MW, Duncan LA, Kirby RL, Good RH, Mennel RG, George TK, Snyder DA, Watkins DL, Denham CA, Hoyes FA, Rubin AS.
    J Clin Oncol; 1996 Nov 15; 14(11):2976-83. PubMed ID: 8918495
    [Abstract] [Full Text] [Related]

  • 6. Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor.
    Stöger H, Samonigg H, Krainer M, Ploszczynski M, Nirnberger G, Maca S, Hehenwarter W, Wirth M, Schüller J, Vavra N, Scheithauer W, Kornek G, Stierer M, Zielinski CC.
    Eur J Cancer; 1998 Mar 15; 34(4):482-8. PubMed ID: 9713297
    [Abstract] [Full Text] [Related]

  • 7. Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group.
    Del Mastro L, Venturini M, Lionetto R, Carnino F, Guarneri D, Gallo L, Contu A, Pronzato P, Vesentini L, Bergaglio M, Comis S, Rosso R.
    J Clin Oncol; 2001 Apr 15; 19(8):2213-21. PubMed ID: 11304774
    [Abstract] [Full Text] [Related]

  • 8. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S, Leonardi V, Danova M, Porta C, Ferrari S, Fincato G, Citarrella P.
    Haematologica; 1999 Nov 15; 84(11):1016-23. PubMed ID: 10553163
    [Abstract] [Full Text] [Related]

  • 9. Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs.
    Aglietta M, Monzeglio C, Pasquino P, Carnino F, Stern AC, Gavosto F.
    Cancer; 1993 Nov 15; 72(10):2970-3. PubMed ID: 8221563
    [Abstract] [Full Text] [Related]

  • 10. Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer.
    O'Shaughnessy JA, Tolcher A, Riseberg D, Venzon D, Zujewski J, Noone M, Gossard M, Danforth D, Jacobson J, Chang V, Goldspiel B, Keegan P, Giusti R, Cowan KH.
    Blood; 1996 Mar 15; 87(6):2205-11. PubMed ID: 8630380
    [Abstract] [Full Text] [Related]

  • 11. The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project.
    Mamounas EP, Anderson S, Wickerham DL, Clark R, Stoller R, Hamm JT, Stewart JA, Bear HD, Glass AG, Bornstein R.
    Am J Clin Oncol; 1994 Oct 15; 17(5):374-81; discussion 382. PubMed ID: 7522393
    [Abstract] [Full Text] [Related]

  • 12. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
    De Placido S, Lauria R, Carlomagno C, Perrone F, De Laurentiis M, Gallo C, Martignetti A, Bellelli T, Limite G, Petrella G, Bianco AR.
    Int J Oncol; 1999 Aug 15; 15(2):339-46. PubMed ID: 10402245
    [Abstract] [Full Text] [Related]

  • 13. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF.
    Ballestrero A, Ferrando F, Garuti A, Basta P, Gonella R, Stura P, Mela GS, Sessarego M, Gobbi M, Patrone F.
    J Clin Oncol; 1999 Apr 15; 17(4):1296. PubMed ID: 10561192
    [Abstract] [Full Text] [Related]

  • 14. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer.
    Honkoop AH, Luykx-de Bakker SA, Hoekman K, Meyer S, Meyer OW, van Groeningen CJ, van Diest PJ, Boven E, van der Wall E, Giaccone G, Wagstaff J, Pinedo HM.
    Oncologist; 1999 Apr 15; 4(2):106-11. PubMed ID: 10337380
    [Abstract] [Full Text] [Related]

  • 15. Failure of GM-CSF to permit dose-escalation in an every other week dose-intensive regimen for advanced breast cancer.
    Osborne CK, Sunderland MC, Neidhart JA, Ravdin PM, Abeloff MD.
    Ann Oncol; 1994 Jan 15; 5(1):43-7. PubMed ID: 8172792
    [Abstract] [Full Text] [Related]

  • 16. Effects of recombinant human granulocyte-macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer.
    Hoekman K, Wagstaff J, van Groeningen CJ, Vermorken JB, Boven E, Pinedo HM.
    J Natl Cancer Inst; 1991 Nov 06; 83(21):1546-53. PubMed ID: 1960751
    [Abstract] [Full Text] [Related]

  • 17. Release of peripheral blood progenitor cells during standard dose cyclophosphamide, epidoxorubicin, 5-fluorouracil regimen plus granulocyte colony stimulating factor for breast cancer therapy.
    Venturini M, Del Mastro L, Melioli G, Balleari E, Garrone O, Pasquetti W, Bason C, Ghio R, Bruzzi P, Rosso R.
    Cancer; 1994 Oct 15; 74(8):2300-6. PubMed ID: 7522948
    [Abstract] [Full Text] [Related]

  • 18. High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer.
    Ardizzoni A, Venturini M, Crinò L, Sertoli MR, Bruzzi P, Pennucci MC, Mariani GL, Garrone O, Bracarda S, Rosso R.
    Eur J Cancer; 1993 Oct 15; 29A(5):687-92. PubMed ID: 8385970
    [Abstract] [Full Text] [Related]

  • 19. Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: increased efficacy and reduced toxicity when given subcutaneously.
    Honkoop AH, Hoekman K, Wagstaff J, van Groeningen CJ, Vermorken JB, Boven E, Pinedo HM.
    Br J Cancer; 1996 Oct 15; 74(7):1132-6. PubMed ID: 8855987
    [Abstract] [Full Text] [Related]

  • 20. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy.
    Bregni M, Siena S, Di Nicola M, Dodero A, Peccatori F, Ravagnani F, Danesini G, Laffranchi A, Bonadonna G, Gianni AM.
    J Clin Oncol; 1996 Feb 15; 14(2):628-35. PubMed ID: 8636780
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.